Smartphone-based monitoring provides objective, personalized functional metrics to evaluate treatment response in pain medicine.
Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. This is an ASCO Meeting Abstract ...
Low baseline ctDNA levels in advanced breast cancer patients predict better response to targeted therapy and longer ...
The classification of uncertain histologies based on cfDNA fragmentomic analysis in patients with uncommon cancers screened for NCI-MATCH. Predictive imaging of the immunotherapy and ...
About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and irritability as well as increased health risks like diabetes and heart risks if ...
Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
A new consensus paper, published by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), the International Osteoporosis ...
AZoLifeSciences on MSN
Integrated micro-optical system revolutionizes tissue monitoring
Microphysiological systems and organ-on-chip technologies are increasingly used to model human tissues outside the body, offering alternatives to animal experiments and traditional cell cultures.
Drug-related problems in HIV treatment are prevalent, affecting treatment effectiveness and safety, with 99.7% of patients experiencing at least one DRP. Treatment safety was the most frequent problem ...
Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 CORAL GABLES, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results